Platelet receptor redox regulation

Platelets

Volumn 19, Issue 1, 2008, Pages 1-8

  Arthur, Jane F ^a   Gardiner, Elizabeth E ^a   Kenny, Dermot ^b   Andrews, Robert K ^a   Berndt, Michael C ^a  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

GPVI; Platelets; Redox

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIOXIDANT; GLYCOPROTEIN; GLYCOPROTEIN 6; HOMODIMER; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; THIOL; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

HEART INFARCTION; HEMOSTASIS; HUMAN; LIGAND BINDING; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; STROKE; THROMBOGENESIS; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; ANTIGENS, CD36; ANTIOXIDANTS; BLOOD PLATELETS; COLLAGEN; CYTOPLASM; DIMERIZATION; HEART DISEASES; HEMOSTASIS; HUMANS; NADPH OXIDASE; OXIDATION-REDUCTION; PLATELET AGGREGATION; PROTEIN STRUCTURE, TERTIARY; QUERCETIN; SIGNAL TRANSDUCTION; STROKE; SUPEROXIDES; THROMBOSIS;

EID: 38649100936     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100701817224     Document Type: Review

References (93)

1. Segal AW. How neutrophils kill microbes. Annu Rev Immunol 2005;23:197-223.
2. Essex DW, Li M. Redox modification of platelet glycoproteins. Curr Drug Targets 2006;7:1233-1241.
3. Blomhoff R. Dietary antioxidants and cardiovascular disease. Curr Opin Lipidol 2005;16:47-54.
4. Diaz MN, Frei B, Vita JA, Keaney JF Jr.. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-416.
5. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. The role of polyphenolic compounds in the diet as inhibitors of platelet function. Proc Nutr Soc 2003;62:469-478.
6. Calzada C, Bruckdorfer KR, Rice-Evans CA. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997;128:97-105.
7. Krotz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004;24:1988-1996.
8. Gorlach A. Redox regulation of the coagulation cascade. Antioxid Redox Signal 2005;7:1398-1404.
9. Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 2003;1:1079-1088.
10. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002;100:917-924.
11. Arthur JF, Shen Y, Kahn ML, Berndt MC, Andrews RK, Gardiner EE. Ligand binding rapidly induces disulfide-dependent dimerization of glycoprotein VI on the platelet plasma membrane. J Biol Chem 2007; 282: 30434-30441.
12. Takaya N, Katoh Y, Iwabuchi K, Hayashi I, Konishi H, Itoh S, Okumura K, Ra C, Nagaoka I, Daida H. Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor γ-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2005;39:856-864.
13. Andrews RK, Berndt MC, Lopez JA. AD Michelson, editor, Academic Press, Platelets. San Diego, CA; 2006, pp 145-164.
14. Arthur JF, Gardiner EE, Matzaris M, Taylor SG, Wijeyewickrema L, Ozaki Y, Kahn ML, Andrews RK, Berndt MC. Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets. Thromb Haemost 2005;93:716-723.
15. 1. Biochem J 2006;398:339-343.
16. Nurden AT, Nurden P. Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol 2003;23:158-159.
17. 1 receptor antagonist. J Thromb Haemost 2003;1:1144-1149.
18. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207.
19. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:15-28.
20. Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007;139:363-372.
21. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998;91:4397-4418.
22. Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D. Glanzmann's thrombasthenia: updated. Platelets 2002;13:387-393.
23. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996;88:1525-1541.
24. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003;197:41-49.
25. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998;101:479-486.
26. Goto S, Tamura N, Handa S, Arai M, Kodama K, Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002;106:266-272.
27. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, Wagner DD. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006;103:16900-16905.
28. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: Impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007;115:2323-2330.
29. Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation 2005;112:2725-2734.
30. Bergmeier W, Rabie T, Strehl A, Piffath C, Prostredna M, Wagner D, Nieswandt B. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost 2004;91:951-958.
31. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 2004;104:3611-3617.
32. Rabie T, Strehl A, Ludwig A, Nieswandt B. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 2005;280:14462-14468.
33. Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH, Wagner DD. Tumor necrosis factor-aconverting enzyme (ADAM17) mediates GPIba shedding from platelets in vitro and in vivo. Circ Res 2004;95:677-683.
34. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007;5:1530-1537.
35. Rabie T, Varga-Szabo D, Bender M, Pozgaj R, Lanza F, Saito T, Watson SP, Nieswandt B. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood 2007;110:529-535.
36. Berndt MC, Karunakaran D, Gardiner EE, Andrews RK. Programmed autologous cleavage of platelet receptors. J Thromb Haemost 2007;5 Suppl 1:212-219.
37. Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006;27:2165-2169.
38. Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors. J Biol Chem 1999;274:29019-29024.
39. Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong X, Debili N, Chickering T, Le Couedic JP, Goodearl A, Dussault B, Fraser C et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000;96:1798-1807.
40. Andrews RK, Suzuki-Inoue K, Shen Y, Tulasne D, Watson SP, Berndt MC. Interaction of calmodulin with the cytoplasmic domain of the platelet membrane glycoprotein VI. Blood 2002;99:4219-4221.
41. Suzuki-Inoue K, Tulasne D, Shen Y, Bori-Sanz T, Inoue O, Jung SM, Moroi M, Andrews RK, Berndt MC, Watson SP. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem 2002;277:21561-21566.
42. Locke D, Liu C, Peng X, Chen H, Kahn ML. Fc Rg-independent signaling by the platelet collagen receptor glycoprotein VI. J Biol Chem 2003;278:15441- 15448.
43. Bori-Sanz T, Suzuki-Inoue K, Berndt MC, Watson SP, Tulasne D. Delineation of the region in the glycoprotein VI tail required for association with the Fc receptor γ-chain. J Biol Chem 2003;278:35914-35922.
44. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102:449-461.
45. 3 signaling in platelets. J Thromb Haemost 2005;3:1752-1762.
46. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004;114:221-233.
47. Berlanga O, Bori-Sanz T, James JR, Frampton J, Davis SJ, Tomlinson MG, Watson SP. Glycoprotein VI oligomerization in cell lines and platelets. J Thromb Haemost 2007;5:1026-1033.
48. Hughan SC, Hughes CE, McCarty OJT, Schweighoffer E, Soultanova I, Ware J, Tybulewicz VLJ, Watson SP. GPVI potentiation of platelet activation by thrombin and adhesion molecules independent of Src kinases and Syk. Arterioscler Thromb Vasc Biol 2007;27:422-429.
49. 1-dependent activation of GPVI. Blood 2006;107:1405-1412.
50. Polgar J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TN, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem 1997;272:13576-13583.
51. Andrews RK, Gardiner EE, Asazuma N, Berlanga O, Tulasne D, Nieswandt B, Smith AI, Berndt MC, Watson SP. A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI. J Biol Chem 2001;276:28092-28097.
52. Wijeyewickrema LC, Gardiner EE, Moroi M, Berndt MC, Andrews RK. Snake venom metalloproteinases, crotarhagin and alborhagin, induce ectodomain shedding of the platelet collagen receptor, glycoprotein VI. Thromb Haemost 2007; 98: 1285-1290.
53. Gardiner EE, Karunakaran D, Arthur JF, Mu FT, Powell MS, Baker RI, Hogarth PM, Kahn ML, Andrews RK, Berndt MC. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: De-ITAMising FcgRIIa. Blood 2008; 111: 165-174.
54. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004;2:2138-2145.
55. Hubbard GP, Wolffram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr 2006;96:482-488.
56. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-1011.
57. Kaneider NC, Mosheimer B, Reinisch N, Patsch JR, Wiedermann CJ. Inhibition of thrombin-induced signaling by resveratrol and quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res 2004;114:185-194.
58. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, Walter U. Platelet NAD(P)H-oxidase-generated ROS production regulates αIIbβ3-integrin activation independent of the NO/cGMP pathway. Blood 2005;106:2757-2760.
59. Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F. Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. Faseb J 2006;20:1082-1089.
60. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181-189.
61. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
62. Salvemini D, Radziszewski W, Mollace V, Moore A, Willoughby D, Vane J. Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. Eur J Pharmacol 1991;199:15-18.
63. Chlopicki S, Olszanecki R, Janiszewski M, Laurindo FR, Panz T, Miedzobrodzki J. Functional role of NADPH oxidase in activation of platelets. Antioxid Redox Signal 2004;6:691-698.
64. Plumb RD, El-Sherbeeny NA, Dixon LJ, Hughes SM, Devine AB, Leahey WJ, McVeigh GE. NAD(P)H-dependent superoxide production in platelets: the role of angiotensin II and protein kinase C. Clin Biochem 2005;38:607-613.
65. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004;110:1326-1329.
66. Takeya R, Sumimoto H. Regulation of novel superoxide-producing NAD(P)H oxidases. Antioxid Redox Signal 2006;8:1523-1532.
67. Wishart MJ, Taylor GS, Dixon JE. , Phoxy lipids: revealing PX domains as phosphoinositide binding modules. 2001;105:817-820.
68. Zalavary S, Grenegard M, Stendahl O, Bengtsson T. Platelets enhance Fcγ receptor-mediated phagocytosis and respiratory burst in neutrophils: the role of purinergic modulation and actin polymerization. 1996;60:58-68.
69. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther 1991;5 Suppl 2:249-268.
70. Stokes KY, Russell JM, Jennings MH, Alexander JS, Granger DN. Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic Biol Med 2007;43:22-30.
71. Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001;106:551-561.
72. Siljander PRM, Munnix ICA, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, Farndale RW, Heemskerk JWM. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004;103:1333-1341.
73. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ Res 2003;93:1225-1232.
74. - from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem 2003;278:47291-47298.
75. 2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia 1999;42:167-176.
76. Tirone F, Cox JA. NADPH oxidase 5 (NOX5) interacts with and is regulated by calmodulin. FEBS Lett 2007;581:1202-1208.
77. Hartfield PJ, Robinson JM. Arachidonic acid activates NADPH oxidase by a direct, calmodulin-regulated mechanism. Prostaglandins Other Lipid Mediat 1998;56:1-6.
78. Zhou Q, Hellermann GR, Solomonson LP. Nitric oxide release from resting human platelets. Thromb Res 1995;77:87-96.
79. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997;100:350-356.
80. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-5197.
81. Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol 1990;101:325-328.
82. 3 as revealed by Raman spectroscopy. Biochemistry 2007;46:6429-6436.
83. Riba R, Sharifi M, Farndale RW, Naseem KM. Regulation of platelet guanylyl cyclase by collagen: evidence that glycoprotein VI mediates platelet nitric oxide synthesis in response to collagen. Thromb Haemost 2005;94:395-403.
84. Riba R, Oberprieler NG, Roberts W, Naseem KM. von Willebrand factor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein Ib-dependent mechanism. J Thromb Haemost 2006;4:2636-2644.
85. Williams RH, Nollert MU. Platelet-derived NO slows thrombus growth on a collagen type III surface. Thromb J 2004;2:1-11.
86. Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006;108:936-942.
87. Adgey AA. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998;135:S43-55.
88. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001;103:399-409.
89. Clutton P, Miermont A, Freedman JE. Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol 2004;24:187-192.
90. Wu RF, Xu YC, Ma Z, Nwariaku FE, Sarosi GA, Jr., Terada LS. Subcellular targeting of oxidants during endothelial cell migration. J Cell Biol 2005;171:893-904.
91. Xu YC, Wu RF, Gu Y, Yang YS, Yang MC, Nwariaku FE, Terada LS. Involvement of TRAF4 in oxidative activation of c-Jun N-terminal kinase. J Biol Chem 2002;277:28051-28057.
92. Wu RF, Gu Y, Xu YC, Nwariaku FE, Terada LS. Vascular endothelial growth factor causes translocation of p47phox to membrane ruffles through WAVE1. J Biol Chem 2003;278:36830-36840.
93. Calaminus SD, McCarty OJ, Auger JM, Pearce AC, Insall RH, Watson SP, Machesky LM. A major role for Scar/WAVE-1 downstream of GPVI in platelets. J Thromb Haemost 2007;5:535-541.